Letteratura Scientifica di Riferimento Consulta l'archivio dei trial clinici e degli studi a supporto del programma formativo. Cliccando su "Leggi Documento", il file si aprirà comodamente in una nuova scheda del browser per facilitarne la lettura e garantirti una navigazione ottimale.
Studio NEJM 1400376
NEJMoa1400376.pdf
Overview Principale
main.pdf
Lymphoma in the BiTE era
Lymphoma-in-the-BiTE-era_lanhae.pdf
CLL Guide for GPs Stage A
L-68-cll-guide-for-gps-managing-stage-a.pdf
Studio JCO 22.02830
jco.22.02830.pdf
Hematol Rep 15-00047
hematolrep-15-00047.pdf
Studio HEM3-8-e144
HEM3-8-e144.pdf
Guidelines Treatment CLL
Guidelines-for-the-treatment-of-chronic-lymphocytic-leukaemia.pdf
Covalent BTK Inhibitors
Covalent_Bruton_tyrosine_kinase_inhibitors_across_.pdf
Correction Lancet Haematol
Correction-to-Lancet-Haematol-2025-12-e978–85_la.pdf
Chronic Lymphocytic Leukaemia
Chronic-Lymphocytic-Leukaemia-CLL.pdf
Acalabrutinib vs Ibrutinib
Acalabrutinib-versus-ibrutinib-in-previously-treated-chronic-lymphocytic-leukemia.pdf
BeiGene JMCP ALPINE
2023April-23028-BeiGene_JMCP_ALPINE_Paper_Spotlight_Final.pdf
Understanding CLL
Understanding-CLL-factsheet.pdf
Treatment Sequencing CLL
TreatmentSequencinginChronicLymphocyticLeukemiain2024WhereWeAreandWhereWeAreHeaded.pdf
Thalassaemia Advocacy
Thalassaemia-advocacy-resilience-and-adaptabili.pdf
Spadafora Safety 2025
Spadafora_Safety_2025.pdf
Studio Cell PIIS14702
PIIS1470204524000706.pdf
Studio Cell PIIS09237
PIIS092375342042469X.pdf
Studio NEJM 1817073
NEJMoa1817073.pdf
Studio NEJM 1815281
NEJMoa1815281.pdf
Addendum NEJM 1815281-1
NEJMoa1815281-1.pdf
Studio NEJM 1812836
NEJMoa1812836.pdf
Studio NEJM 1713976
NEJMoa1713976.pdf
Studio NEJM 1509388
NEJMoa1509388.pdf